VistaGen Therapeutics, Inc. (NASDAQ:VTGN) Sees Large Growth in Short Interest

VistaGen Therapeutics, Inc. (NASDAQ:VTGN) was the target of a significant increase in short interest during the month of April. As of April 15th, there was short interest totaling 1,711,402 shares, an increase of 21.3% from the March 31st total of 1,410,489 shares. Based on an average daily volume of 628,257 shares, the short-interest ratio is currently 2.7 days. Approximately 4.4% of the shares of the company are sold short.

Institutional Investors Weigh In On VistaGen Therapeutics

Several institutional investors and hedge funds have recently bought and sold shares of VTGN. Virtu Financial LLC purchased a new stake in VistaGen Therapeutics in the 4th quarter worth approximately $25,000. Cubist Systematic Strategies LLC bought a new position in VistaGen Therapeutics during the 1st quarter valued at approximately $25,000. Schonfeld Strategic Advisors LLC bought a new position in VistaGen Therapeutics during the 3rd quarter valued at approximately $39,000. Seven Fleet Capital Management LP bought a new position in VistaGen Therapeutics during the 4th quarter valued at approximately $42,000. Finally, Tudor Investment Corp ET AL bought a new position in VistaGen Therapeutics during the 4th quarter valued at approximately $50,000. Hedge funds and other institutional investors own 78.39% of the company’s stock.

Analysts Set New Price Targets

VTGN has been the topic of several research analyst reports. Wall Street Zen cut VistaGen Therapeutics from a “hold” rating to a “sell” rating in a research report on Saturday, March 21st. Weiss Ratings reiterated a “sell (d-)” rating on shares of VistaGen Therapeutics in a research note on Wednesday, January 21st. Four investment analysts have rated the stock with a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, VistaGen Therapeutics has an average rating of “Reduce” and a consensus price target of $0.95.

VistaGen Therapeutics Trading Up 2.0%

VTGN opened at $0.63 on Friday. The stock has a 50-day moving average price of $0.59 and a 200-day moving average price of $1.79. VistaGen Therapeutics has a 12-month low of $0.43 and a 12-month high of $5.14. The stock has a market capitalization of $24.79 million, a P/E ratio of -0.33 and a beta of 0.31.

VistaGen Therapeutics (NASDAQ:VTGN) last issued its earnings results on Thursday, February 12th. The company reported ($0.45) earnings per share for the quarter, beating the consensus estimate of ($0.51) by $0.06. The company had revenue of $0.30 million for the quarter, compared to analysts’ expectations of $0.14 million. On average, equities research analysts predict that VistaGen Therapeutics will post -1.88 EPS for the current year.

VistaGen Therapeutics Company Profile

VistaGen Therapeutics, Inc (NASDAQ:VTGN) is a clinical-stage biopharmaceutical company dedicated to the discovery and development of next-generation medicines for central nervous system disorders. Incorporated in Delaware in 1998 and headquartered in South San Francisco, California, VistaGen applies advanced human pluripotent stem cell technologies to accelerate drug candidate validation and optimization. The company’s core focus is on addressing unmet medical needs in major depressive disorder, neuropathic pain and dermatological conditions.

The company’s lead candidate, AV-101, is an oral prodrug designed to modulate glutamatergic neurotransmission via the N-methyl-D-aspartate (NMDA) receptor pathway, with clinical programs targeting major depressive disorder and neuropathic pain.